TFRC and head and neck squamous cell carcinoma: HPV+ HNSCC or HPV- HNSCC patient PB T lymphocyte (CD3+) CD71+ (%) or monocyte 24 hours in vitro LPS-stimulated IL-6 secretion (pg/ml).